Clinical Trials
8 trialsNCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT00718549 2018-08-20
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Phase 3 Completed
NCT02072811 2014-02-27
PALG-AML2012
Polish Adult Leukemia Group
Phase 3 Unknown
NCT00136084 2012-12-05
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00003746 2012-05-15
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
Swiss Cancer Institute
Phase 3 Completed